Class information for:
Level 1: CONTINUAL REASSESSMENT METHOD//DOSE FINDING//DOSE FINDING STUDIES

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
11877 883 26.9 72%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
970 10197 CAUSAL INFERENCE//PRINCIPAL STRATIFICATION//STATISTICS IN MEDICINE

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CONTINUAL REASSESSMENT METHOD Author keyword 188 89% 10% 84
2 DOSE FINDING Author keyword 68 47% 12% 107
3 DOSE FINDING STUDIES Author keyword 33 74% 3% 25
4 PHASE I TRIALS Author keyword 28 43% 6% 49
5 MAXIMUM TOLERATED DOSE Author keyword 20 29% 7% 59
6 ESCALATION WITH OVERDOSE CONTROL Author keyword 17 100% 1% 8
7 UP AND DOWN DESIGN Author keyword 15 88% 1% 7
8 BAYESIAN ADAPTIVE DESIGN Author keyword 12 63% 1% 12
9 PHASE I TRIAL Author keyword 11 18% 7% 58
10 PHASE 1 TRIALS Author keyword 10 61% 1% 11

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 CONTINUAL REASSESSMENT METHOD 188 89% 10% 84 Search CONTINUAL+REASSESSMENT+METHOD Search CONTINUAL+REASSESSMENT+METHOD
2 DOSE FINDING 68 47% 12% 107 Search DOSE+FINDING Search DOSE+FINDING
3 DOSE FINDING STUDIES 33 74% 3% 25 Search DOSE+FINDING+STUDIES Search DOSE+FINDING+STUDIES
4 PHASE I TRIALS 28 43% 6% 49 Search PHASE+I+TRIALS Search PHASE+I+TRIALS
5 MAXIMUM TOLERATED DOSE 20 29% 7% 59 Search MAXIMUM+TOLERATED+DOSE Search MAXIMUM+TOLERATED+DOSE
6 ESCALATION WITH OVERDOSE CONTROL 17 100% 1% 8 Search ESCALATION+WITH+OVERDOSE+CONTROL Search ESCALATION+WITH+OVERDOSE+CONTROL
7 UP AND DOWN DESIGN 15 88% 1% 7 Search UP+AND+DOWN+DESIGN Search UP+AND+DOWN+DESIGN
8 BAYESIAN ADAPTIVE DESIGN 12 63% 1% 12 Search BAYESIAN+ADAPTIVE+DESIGN Search BAYESIAN+ADAPTIVE+DESIGN
9 PHASE I TRIAL 11 18% 7% 58 Search PHASE+I+TRIAL Search PHASE+I+TRIAL
10 PHASE 1 TRIALS 10 61% 1% 11 Search PHASE+1+TRIALS Search PHASE+1+TRIALS

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CONTINUAL REASSESSMENT METHOD 204 60% 25% 220
2 I CLINICAL TRIALS 70 52% 11% 97
3 I II CLINICAL TRIALS 49 94% 2% 17
4 I TRIALS 44 85% 3% 23
5 LATE ONSET TOXICITIES 38 76% 3% 26
6 MOLECULARLY TARGETED AGENTS 27 92% 1% 11
7 PHASE I TRIALS 22 43% 5% 40
8 ONCOLOGY TRIALS 21 48% 4% 31
9 OVERDOSE CONTROL 17 72% 1% 13
10 DOWN DESIGN 14 64% 2% 14

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Designs of drug-combination phase I trials in oncology: a systematic review of the literature 2015 1 28 75%
Dose Escalation Methods in Phase I Cancer Clinical Trials 2009 109 73 59%
Adaptive designs for dual-agent phase I dose-escalation studies 2013 4 72 85%
Life-expectancy of patients enrolled in phase 1 clinical trials: A systematic review of published prognostic models 2012 5 20 95%
Principles of dose finding studies in cancer: a comparison of trial designs 2013 2 28 86%
Meta-analysis of the Relationship Between Dose and Benefit in Phase I Targeted Agent Trials 2012 8 12 50%
Experimental designs for phase I and phase I/II dose-finding studies 2006 31 13 69%
A New Model for Determining the MTD During Phase-I Trials in Pediatric Oncology 2012 3 8 75%
ICH S9: Developing Anticancer Drugs, One Year Later 2011 3 5 80%
Phase I studies of chemotherapeutic agents in cancer patients: A review of the designs 2006 15 65 89%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 TRANSLAT PL STAT 6 53% 0.9% 8
2 UNIT EA2694 4 75% 0.3% 3
3 UNIT MOL THER Y CANC 3 100% 0.3% 3
4 ETH HUMANITIES SPIRITUAL CARE 3 30% 0.8% 7
5 QUAL LIFE PALLIAT CARE 2 44% 0.5% 4
6 PL DEV SUPPORT DIRECTORATE 2 36% 0.6% 5
7 PHASE CLIN TRIALS PROGRAM 2 67% 0.2% 2
8 UNITE 436 2 67% 0.2% 2
9 EQUIPE ACCUEIL ST PUBL EPIDEMIOL MODELISAT MALA 2 50% 0.3% 3
10 MED PHARMACEUT STAT UNIT 2 12% 1.6% 14

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000103116 CONDITIONAL POWER//INTERIM ANALYSIS//SAMPLE SIZE RE ESTIMATION
2 0.0000097151 PATIENT RECRUITMENT//MINORITY RECRUITMENT//TRIAL PARTICIPATION
3 0.0000083959 INTERACTION CONDITION//TARGETED CLINICAL TRIALS//INFLUENCE CONDITION
4 0.0000080732 D OPTIMALITY//APPROXIMATE DESIGNS//APPROXIMATE DESIGN
5 0.0000060964 RESPONSE ADAPTIVE DESIGN//DOUBLY ADAPTIVE BIASED COIN DESIGN//RESPONSE ADAPTIVE DESIGNS
6 0.0000058009 MANAGEMENT HEALTHCARE//RESEARCH NURSE//CLINICAL RESEARCH COORDINATORS
7 0.0000057718 EQUIPOISE//SHAM SURGERY//DEVELOPING WORLD BIOETHICS
8 0.0000054420 KLIN DERMATOL DERMATOL ALLERGOL//COLLECTIVE ETHICS//DRUG EXAMINATION
9 0.0000051195 SERV PSYCHIAT MENTAL HLTH//SYMPTOMATIC VOLUNTEERS//UNDUE INDUCEMENT
10 0.0000048829 ASSENT//RESEARCH PARTICIPATION DECISION MAKING//NON THERAPEUTIC RESEARCH